27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Iterum Therapeutics plc (NASDAQ:ITRM) has agreed with the FDA under the special protocol assessment (SPA) process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sulopenem etzadroxil-probenecid for uncomplicated urinary tract infections.
- The pivotal study under the SPA agreement is designed as a non-inferiority trial comparing oral sulopenem and Augmentin (amoxicillin/clavulanate).
- Related: Iterum Expects To Start Additional Sulopenem Trial In Urinary Tract Infections In 2H22.
- Patients will be randomized to receive either oral sulopenem twice daily for five days or Augmentin twice daily for five days.
- The primary endpoint is the overall response at Day 12 of the study.
- The study is expected to enroll approximately 1,966 patients and is anticipated to start enrolling in the fourth quarter of 2022.
- The Company has already commenced study start-up activities to enable timely initiation and recruitment.
- Price Action: ITRM shares are up 62.10% at $0.39 during the market session on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!